Forte Biosciences Past Earnings Performance
Past criteria checks 0/6
Forte Biosciences's earnings have been declining at an average annual rate of -2.4%, while the Biotechs industry saw earnings growing at 13.4% annually.
Key information
-2.4%
Earnings growth rate
60.5%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -210.8% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Forte Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -36 | 17 | 20 |
| 31 Mar 24 | 0 | -32 | 12 | 21 |
| 31 Dec 23 | 0 | -31 | 11 | 22 |
| 30 Sep 23 | 0 | -30 | 10 | 21 |
| 30 Jun 23 | 0 | -24 | 8 | 16 |
| 31 Mar 23 | 0 | -18 | 9 | 10 |
| 31 Dec 22 | 0 | -14 | 8 | 6 |
| 30 Sep 22 | 0 | -12 | 8 | 4 |
| 30 Jun 22 | 0 | -17 | 8 | 9 |
| 31 Mar 22 | 0 | -19 | 8 | 11 |
| 31 Dec 21 | 0 | -22 | 8 | 14 |
| 30 Sep 21 | 0 | -23 | 7 | 16 |
| 30 Jun 21 | 0 | -20 | 6 | 14 |
| 31 Mar 21 | 0 | -49 | 5 | 12 |
| 31 Dec 20 | 0 | -46 | 4 | 10 |
| 30 Sep 20 | 0 | -43 | 3 | 8 |
| 30 Jun 20 | 0 | -39 | 2 | 5 |
| 31 Mar 20 | 0 | -5 | 2 | 3 |
| 31 Dec 19 | 0 | -4 | 1 | 3 |
Quality Earnings: 37T is currently unprofitable.
Growing Profit Margin: 37T is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 37T is unprofitable, and losses have increased over the past 5 years at a rate of 2.4% per year.
Accelerating Growth: Unable to compare 37T's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 37T is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.6%).
Return on Equity
High ROE: 37T has a negative Return on Equity (-210.82%), as it is currently unprofitable.